Propel asco gu 2023 2023 ASCO GU Cancers Symposium. Feb 21, 2023 · Background: TALAPRO-2 (NCT03395197) is the first phase 3 study to combine the poly(ADP-ribose) polymerase inhibitor TALA with the androgen receptor inhibitor ENZA. Christian Kollmannsberger discuss practice-changing abstracts that were presented at the 2023 ASCO Genitourinary Cancers Symposium, including results from the TALAPRO-2, PROpel, TRITON3, ARASENS, KEYNOTE-057, CheckMate 274, and CheckMate 9ER studies. Notes. Prostate cancer (UroToday. Figures for ASCO-GU 2023. --(BUSINESS WIRE)-- AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the key secondary endpoint of overall survival (OS) from the Phase 3 PROpel trial evaluating LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred), compared to placebo plus abi/pred. Clinical Advances in Hematology & Oncology Volume 21, Issue 4 April 2023 199 Highlights in Prostate Cancer From the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium February 16-18, 2023 • San Francisco, California and Virtual talazoparib group than in the placebo group (23%). –18. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Mar 3, 2023 · 2023年美国临床肿瘤学会泌尿男生殖系肿瘤分会（asco-gu）年会于当地时间2023年2月16日至18日在旧金山盛大召开。 PARPi在前列腺癌领域继续大放异彩，多项 PARPi 联合 新型内分泌治疗（NHT）药物的三期临床研究陆续发布结果，同源重组修复基因突变（HRRm）mCRPC 人群 Mar 3, 2023 · Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Silke Gillessen discussing treatment sequencing and combinations for metastatic castration-resistant prostate cancer Aug 25, 2023 · 1. ASCO GU 2023 overall survival results in PROpel, advanced prostate cancer, abiraterone and olaparib versus abiraterone and placebo as first-line therapy for mCRPC, DNA repair in prostate cancer, PARP and androgen receptor inhibition. Feb 16, 2023 · Noel Clarke, Urological Surgeon and Professor of Urological Oncology at Manchester’s Christie/Salford Royal Hospitals and Manchester University, and a senior investigator in the PROpel trial, said: “From the primary radiographic progression-free survival analysis presented at ASCO GU last year to the updated overall survival data presented (UroToday. J. ASCO GU 2022 PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). 2023, in San Francisco stattfand, hatte wieder einige neue Daten insbesondere zur Poly(ADP-ribose)- Polymerasen (PARP) Inhibition (PARPi) beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) zu bieten. This study aimed to determine oncologists’ perceptions of these new data. ASCO GU 2024 post-hoc analysis of PROpel, efficacy of combination olaparib plus abiraterone acetate/prednisone versus placebo plus abiraterone acetate/prednisone, metastatic castration-resistant prostate cancer (mCRPC), homologous recombination repair (HRR) gene mutations. Apr 28, 2023 · PROpel: First-line Abiraterone Plus Olaparib in mCRPC. Pts unselected for genetic alterations in DNA damage repair pathways, directly or indirectly involved with homologous recombination repair (HRR), received either TALA + ENZA or PBO + ENZA as 1L treatment for mCRPC. Feb 17, 2023 · At the 2023 ASCO GU Symposium, Alan Bryce, MD, presented results from the TRITON3 study on rucaparib vs physician’s choice. Feb 17, 2023 · ASCO GU 2023. 02. Median OS ASCO GU 2023 Kidney Cancer. Feb 21, 2023 · Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). Fred Saad and colleagues presenting results of the PROpel phase 3 trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic Adherence to ASCO Language of Respect (LoR) guidelines in urothelial carcinoma (UC) abstracts at the 2023 ASCO Annual Meeting. The phase III PROpel trial evaluated abiraterone plus olaparib vs abiraterone plus placebo as first‑line treatment of biomarker‑unselected mCRPC. Feb 16, 2023 · RAHWAY, N. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. Neeraj Agarwal and Dr. Published Background: TALAPRO-2 (NCT03395197) is the first phase 3 study to combine the poly(ADP-ribose) polymerase inhibitor TALA with the androgen receptor inhibitor ENZA. Presented February 16, 2023. The Language of Respect (LoR) guidelines of ASCO were developed to promote patient-centered language and demonstrate the highest levels of respect and empathy when referring to people with cancer. Noel Clarke discussing the final overall survival results in PROpel, a phase 3 trial assessing abiraterone and olaparib versus abiraterone and placebo as first-line therapy for mCRPC. The trial's primary endpoint was Two recent trials, TALAPRO-2 and PROpel, evaluate PARPis plus an androgen receptor pathway inhibitor for patients both with and without genetic mutations were presented at ASCO GU 2023. ASCO 2023, prostate cancer, PARP inhibitors, Homologous Recombination Repair (HRR), PROpel trial, metastatic castration resistant prostate cancer (mCRPC), MAGNITUDE trial, TALAPRO trial, TALAPRO 2 trial, HRR mutations, PARPi/ARSI combination. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. Feb 27, 2023 · アストラゼネカのリムパーザ、第Ⅲ相PROpel試験の主要な副次評価項目である全生存期間の最終結果がASCO GUで発表 公開日 2023年 2月 27日 本資料はアストラゼネカ英国本社が 2023年2月16日に発信したプレスリリース を日本語に翻訳し、みなさまのご参考に提供 Mar 2, 2023 · Guest host Dr. The Genitourinary Cancers Symposium is funded through Conquer Cancer ®, the ASCO Foundation, by these generous donors. com) The 2023 GU ASCO annual meeting included a session on advanced prostate cancer, specifically new targets, new drugs, and new victories, featuring a presentation by Dr. Der diesjährige ASCO GU, der vom 16. February 16-18, 2023. 2. Feb 16, 2023 · In the primary analysis presented at ASCO GU 2022, and published in The New England Journal of Medicine Evidence, PROpel met its primary endpoint of radiographic progression-free survival (rPFS), showing that LYNPARZA in combination with abiraterone significantly reduced the risk of disease progression or death by 34% versus abiraterone alone Feb 24, 2023 · Noel Clarke, MBBS, FRCS, ChM, Consultant Urologist, Salford Royal Hospital, explains the PROpel study design, what the overall survival data shows at data cutoff 3, and the further analysis needed to help validate the abiraterone-plus-olaparib combination as a first-line option for patients with mCRPC. . Feb 16, 2023 · PROpel was an international, phase 3 trial that randomly assigned 796 patients with mCRPC to olaparib at full dose (300 mg twice daily) plus abiraterone and prednisone/prednisolone or to abiraterone plus prednisone alone. Lynparza in combination with abiraterone and prednisone or prednisolone is approved in the EU and several other countries for the treatment of adult patients with mCRPC based on the PROpel trial. 66, 95% confidence interval [CI] (UroToday. ASCO GU 2023: The Ever-Changing Pathologic Classification of Renal Cell Carcinoma; ASCO GU 2023: Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate in Metastatic Renal Cell Carcinoma. 2025 Sponsorship Donors (Gold) 2025 Sponsorship Donors (Silver) Feb 13, 2025 · Initial results, presented at ASCO-GU 2023, found a 37% reduction in the risk of disease progression or death in all comers, an effect clearly driven by the HRR-deficient subgroup, where the risk reduction was 55%. Feb 17, 2023 · In the primary analysis presented at ASCO GU 2022, and published in The New England Journal of Medicine Evidence,(previously cited) PROpel met its primary endpoint of radiographic progression-free survival (rPFS), showing that Lynparza in combination with abiraterone significantly reduced the risk of disease progression or death by 34% versus Mar 2, 2023 · Further results from the final prespecified overall survival (OS) analysis were presented at ASCO GU 2023. com) The 2022 GU ASCO Annual meeting included a prostate cancer oral abstract session featuring Dr. Abstract LBA16. Noel Clarke, MBBS, FRCS, ChM, explains the PROpel study design and what the overall survival data shows at data cutoff 3. Jan 29, 2024 · 165Background: PROpel (NCT03732820) met its primary endpoint and showed a significant investigator-assessed radiographic progression-free survival (rPFS) benefit with O + A vs P + A in first-line mCRPC (hazard ratio [HR] 0. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al: Final overall survival in PROpel: Abiraterone and olaparib versus abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer. iuc ugxrxh dwtkc fjpyad obdp zhxpl aaf xdmvu ebj loxhk tsjlmk mklo rszhu zlwcgf slwvm